X4 Pharmaceuticals Inc
NASDAQ:XFOR
X4 Pharmaceuticals Inc
NASDAQ:XFOR
Price:
1.115 USD
3.24%
Updated:
May 3, 2024
X4 Pharmaceuticals Inc
Cash from Financing Activities
|
X4 Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
X4 Pharmaceuticals Inc
NASDAQ:XFOR
|
Cash from Financing Activities
$88.5m
|
CAGR 3-Years
93%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is X4 Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
88.5m
USD
88.5m
USD
Based on the financial report for Dec 31, 2023, X4 Pharmaceuticals Inc's Cash from Financing Activities amounts to 88.5m USD.
What is X4 Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
93%
93%
Over the last year, the Cash from Financing Activities growth was -24%. The average annual Cash from Financing Activities growth rates for X4 Pharmaceuticals Inc have been 93% over the past three years .
You don't have any saved screeners yet
